In summary, while E-Cadherin loss in corticotropinomas, similar to other subtypes of pituitary tumors, seems to be involved in tumor dedifferentiation and EMT-like changes, its clinical utility as a biomarker for invasiveness or a poor prognosis in Cushing’s disease remains uncertain. The gene discussed is CDH1; the disease is neoplasm.